Table 1.
Clinical Form | |||
---|---|---|---|
Cutaneous Lymphatic | Cutaneous Fixed | Cutaneous-Disseminated | |
No. of patients | 32 (58.2%) | 19 (34.6%) | 4 (7.2%) |
Positive response to sporotricin M | 32/32 (100%) | 19/19 (100%) | 1/4 (25%) |
Normal-positive reaction (0.5–2 cm) | 22/32 (68.7%) | 2/19 (10.5%) | 1/4 (25.0%) |
Hyperergic-positive reaction (>2 cm) | 10/32 (31.3%) | 17/19 (89.5%) | None |